Infertility, In Vitro Fertilization
Conditions
Keywords
Pharmacological effects of drugs, Hormones, Hormone substitutes and Hormone Antagonists, Pharmacological Actions, Randomized, Multi-center, Multi-national
Brief summary
The primary objective of this trial was to investigate the appropriate dose of a single injection of Org 36286 to initiate multifollicular growth for the first seven days in a controlled ovarian hyperstimulation (COH) protocol for IVF and IVF/ICSI. After seven days, participants were converted to treatment with Puregon® 150 IU and administration of the GnRH antagonist Orgalutran® to finalize the stimulation cycle. Secondary objectives were the safety (including the absence of antibody formation) and the direct effects of Org 36286 on reproductive functions (steroidogenesis, oocyte maturation, embryo quality and implantation).
Detailed description
This trial was made up of two stages with different designs and was conducted at two clinical trial sites. Stage I was open-label and uncontrolled in a small cohort of women (n=6) to obtain first experience in employing Org 36286 in women meeting all inclusion and none of the exclusion criteria. Based on the results of a previous study, the most appropriate dose was anticipated to be 120 μg Org 36286, which was administered on Cycle Day 2 or 3. After seven days, treatment was continued with a fixed dose of 150 IU Puregon® SC. If the size of the leading follicle was \>=14 mm, 0.25 mg Orgalutran® SC once daily was administered concurrently with 150 IU Puregon® up to and including the day of hCG. The maximum total treatment duration was 19 days. Treatment of the first two participants with Org 36286 120 μg, that was expected to be adequate for COH, was cancelled due to disrupted follicular growth beyond Day 7. Therefore, the dose of Org 36286 was adapted from 120 μg to 180 µg. Treatment of the first participants gave an indication of the validity of the anticipated doses to be used in Stage II, the actual dose-finding trial. Stage II was open-label, prospective and randomized, comparing three experimental regimens differing in dose of Org 36286 (120 μg, 180 μg, or 240 μg) with a reference treatment. Post-treatment assessments were completed at the visit two weeks after embryo transfer.
Interventions
DRUGOrg 36286
Intra-abdominal injection of Org 36286
DRUGPuregon®
Subcutaneous Puregon® 150 IU
DRUGOrgalutran®
Subcutaneous Orgalutran® 0.25 mg
DRUGPregnyl®
Subcutaneous Pregnyl® 10,000 IU
Sponsors
Organon and Co
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 39 Years
Healthy volunteers
No
Inclusion criteria
* Females of couples with an indication for COH and IVF or IVF/ICSI; * Body mass index (BMI) \>=18 and \<=29 kg/m\^2; * Normal menstrual cycle length: 24-35 days; * Ejaculatory sperm;
Exclusion criteria
* History of/or current endocrine abnormality such as polycystic ovary syndrome (PCOS), or polycystic ovaries according to ultrasound scan (USS), (treated) hyperprolactinemia or evidence of ovarian dysfunction; * More than three unsuccessful COH cycles for IVF since the last established ongoing pregnancy (if applicable); * History of non- or low ovarian response to FSH/human menopausal gonadotropin (hMG) treatment; * Any clinically relevant hormone value outside the reference range during the early follicular phase (menstrual Cycle Day 2-7) as measured by the local laboratory (FSH, luteinizing hormone \[LH\], estradiol \[E2\], progesterone \[P\], total testosterone \[T\], thyroid stimulating hormone \[TSH\], and prolactin); * Any clinically relevant abnormal laboratory value; * Any ovarian and/or abdominal abnormality interfering with ultrasound examination; * Contraindications for the use of gonadotropins (e.g. tumors, pregnancy/lactation, undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts); * Epilepsy, diabetes, cardiovascular, gastro-intestinal, hepatic, renal, pulmonary, or abdominal disease; * History or presence of alcohol or drug abuse within 12 months prior to signing informed consent; * Hypersensitivity to Orgalutran® or any of its components; * Administration of investigational drugs within three months prior to screening. * Use of hormonal preparations within one month prior to the start of Org 36286 with the exception of thyroid medication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Median Puregon® Dose (IU) Required To Reach Criteria for Administration of Human Chorionic Gonadotropin (hCG) For Induction of Final Oocyte Maturation | Day 8 Up to End of Menstrual Cycle |
Secondary
| Measure | Time frame |
|---|---|
| Number of Cumulus-Oocyte-Complexes Experienced By Participants During One Menstrual Cycle | Up to End of Menstrual Cycle |
| Number of Good Quality Embryos Obtained | Up to One Menstrual Cycle |
| Number of Participants With Ongoing Pregnancies | Up to 10 Weeks Following hCG Administration |
| Number of Participants Experiencing Cancellation of Menstrual Cycle | Up to End of Menstrual Cycle |
| Number of Participants With Abnormal Laboratory Findings | Up to 2 Weeks Following Embryo Transfer |
| Number of Participants With Abnormal Vital Signs | Up to 2 Weeks Following Embryo Transfer |
| Number of Participants With Serious Adverse Events (SAEs) | Up to 2 Weeks Following Embryo Transfer |
| Number of Participants With Anti-Org 36286 Antibodies | Up to 2 Weeks Following Embryo Transfer |
Outcome results
None listed